Multiple Doses of DM199 in Patients With Chronic Kidney Disease (REDUX)
Kidney DiseasesAn open-label, Phase II, multi-center study evaluating multiple doses of DM199 in participants with chronic kidney disease.
A Study to Assess the Effect of Verinurad on the Electric Activity of the Heart
Healthy Volunteers (Intended Indication: Chronic Kidney Disease)This study will be conducted to investigate the safety of verinurad in healthy volunteers in combination with allopurinol 300 mg, compared with placebo in particular its effect on electrocardiogram (ECG), with focus on the QT/QTc interval
Low-Phosphate Diet and Fibroblast Growth Factor-23 Level
Chronic Kidney Disease Requiring Chronic DialysisHyperphosphatemia2 moreThe aims of the study are to evaluate the effect of low-phosphate diet on FGF23 level and to determine the optimal amount of dietary phosphate restriction in hemodialysis patients. In particular, the investigators will assess the comparing effect of pre-specified low-phosphate diets, very low-phosphate diet, phosphate-to-protein ratio (PPR) value of 8 mg/g, versus low-phosphate diet, PPR value of 10 mg/g, on the change of FGF23 and phosphate level.
Head-to-Head Study of Etelcalcetide and Cinacalcet in Asian Hemodialysis Patients With Secondary...
Secondary HyperparathyroidismChronic Kidney DiseaseThe primary objective is to demonstrate that treatment with etelcalcetide (AMG 416) is not inferior to treatment with cinacalcet for lowering serum intact parathyroid hormone (PTH) levels by > 30% from baseline among participants with chronic kidney disease (CKD) and secondary hyperparathyroidism (SHPT) who require management with hemodialysis.
Study Exploring the Effect of Crizanlizumab on Kidney Function in Patients With Chronic Kidney Disease...
Sickle Cell Disease (SCD)The goal of the study is to evaluate descriptively the effect of crizanlizumab + standard of care and standard of care alone on renal function in sickle cell disease patients ≥ 16 years with chronic kidney disease due to sickle cell nephropathy.
Primary Care CKD Registry
HypertensionChronic Kidney DiseasesThis study examines whether a safety-net primary care CKD registry directed at the entire primary care team can enhance the delivery of guideline concordant CKD care, including BP control, ACEi/ARB use and albuminuria quantification.
Hospital-Level Care at Home for Acutely Ill Adults
InfectionHeart Failure7 moreThe investigators propose a home hospital model of care that substitutes for treatment in an acute care hospital. Limited studies of the home hospital model have demonstrated that a sizeable proportion of acute care can be delivered in the home with equal quality and safety, reduced cost, and improved patient experience.
A Study to Evaluate Safety and Effects of Sotagliflozin 400 and 200 mg on Glucose Control in Participants...
Type 2 Diabetes MellitusChronic Kidney Disease Stage 4Primary Objective: To demonstrate the superiority of sotagliflozin 400 milligrams (mg) versus placebo with respect to hemoglobin A1c (HbA1c) reduction at Week 26 in participants with Type 2 diabetes who have inadequate glycemic control and severe renal impairment Secondary Objectives: To assess the effects of sotagliflozin 200 mg versus placebo based on change from baseline in HbA1c To assess the effects of sotagloflozin 400 mg and 200 mg versus placebo To evaluate the safety of sotagliflozin 400 mg and 200 mg versus placebo
Safety and Efficacy Study of Sotagliflozin on Glucose Control in Participants With Type 2 Diabetes,...
Type 2 Diabetes MellitusChronic Kidney Disease Stage 3Primary Objective: To demonstrate the superiority of Sotagliflozin 200 milligrams (mg) and Sotagliflozin 400 mg versus placebo on HbA1c reduction at 26 Weeks in participants with Type 2 diabetes who have inadequate glycemic control and moderate renal impairment. Secondary Objectives: To assess the effects of Sotagliflozin 200 mg and 400 mg versus placebo with respect to additional measures of glycemic control, blood pressure, and body weight. To evaluate the safety of Sotagliflozin 200 mg and 400 mg versus placebo.
A Long-Term Follow-Up Study of Participants Exposed to REACT
Diabetic Kidney DiseaseChronic Kidney DiseasesThe purpose of this study is to evaluate the long-term safety of up to two gelatin-hydrogel formulation REACT injections given 3 to 6 months apart and delivered percutaneously into same kidney on renal function in participants with chronic kidney disease (CKD).